<ul><li>Cigna Group plans to limit out-of-pocket medication expenses for US patients, in response to increasing scrutiny of pharmacy benefit managers (PBMs) in prescription drug pricing.</li><li>The changes aim to ensure patients benefit directly from negotiated discounts and rebates, preventing them from paying the full list price for medications.</li><li>Cigna's initiative also protects patients with high out-of-pocket costs by ensuring they don't pay more for their medication than their employer contributes, directing rebate dollars more directly to patient cost-sharing.</li><li>While these changes are seen as positive, they may not significantly impact the overall market. Stuart Piltch, a healthcare and insurance expert, emphasizes the need for a more comprehensive approach to address high drug costs.</li></ul>

Stuart Piltch Offers Insight on Cigna’s Initiative to Lower Patient Drug Costs

Discover more